ライフサイエンスコーパス: smallpox

1 threat variola virus (the causative agent of smallpox).

2 us and Variola virus (the causative agent of smallpox).

3 y responses elicited by immunization against smallpox.

4 opoxvirus related to the virus causing human smallpox.

5 played a crucial role in the eradication of smallpox.

6 where it causes disease in humans resembling smallpox.

7 irus (ECTV) infection, a surrogate model for smallpox.

8 mic, febrile-rash illness closely resembling smallpox.

9 have efficacy in protecting individuals from smallpox.

10 ted to variola virus, the causative agent of smallpox.

11 irus that was used as a vaccine to eradicate smallpox.

12 with the goal to identify safer vaccines for smallpox.

13 related to variola, the etiological agent of smallpox.

14 closely related to variola virus that causes smallpox.

15 h, most notably including the eradication of smallpox.

16 although usually less severe, than those of smallpox.

17 nesis and to develop a safer vaccine against smallpox.

18 luding variola virus, the causative agent of smallpox.

19 anticipated to be equally effective against smallpox.

20 luding variola virus, the causative agent of smallpox.

21 otection against variola virus, the agent of smallpox.

22 isting or new generation VV vaccines against smallpox.

23 irus, a close relative of the virus of human smallpox.

24 exhibit improved protective efficacy against smallpox.

25 ctive component of a subunit vaccine against smallpox.

26 lates many of the clinical features of human smallpox.

27 A, varicella, Streptococcus pneumoniae, and smallpox.

28 virus and that is the mouse homolog of human smallpox.

29 tries, including the complete eradication of smallpox.

30 first human pathogen to be eradicated since smallpox.

31 e infections can occur after vaccination for smallpox.

32 rting its use as a surrogate model for human smallpox.

33 thal mousepox, the mouse equivalent of human smallpox.

34 ents a potential surrogate disease model for smallpox.

35 e men had never received vaccination against smallpox.

36 ice infected with vaccinia virus, a model of smallpox.

37 ere in circulation before the eradication of smallpox.

38 cancer since its use for the eradication of smallpox.

39 Orthopoxvirus with a presentation similar to smallpox.

40 ion of variola virus, the etiologic agent of smallpox.

41 measles (11.7 days), varicella (14.0 days), smallpox (17.7 days), mumps (18.0 days), rubella (18.3 d

42 f tecovirimat for the antiviral treatment of smallpox, a disease that has been eradicated from the wo

43 and safer vaccine to protect people against smallpox, a monkeypox model of infection in cynomolgus m

44 cine strain that is efficacious against both smallpox and anthrax due to the integration of immune-en

45 Biological weapons such as smallpox and anthrax had the potential to cause a nation

46 ugh licensed vaccines are available for both smallpox and anthrax, because of inadequacies associated

47 (VV) has been used as a vaccine to eradicate smallpox and as a vaccine for HIV and tumors.

48 The detection algorithm performed better for smallpox and botulism than for anthrax and tularemia.

49 tion results in a disease that is similar to smallpox and can also be fatal.

50 ch constitutes the vaccine used to eradicate smallpox and is a candidate vector for other infectious

51 In humans, MPXV causes a disease similar to smallpox and is considered to be an emerging infectious

52 ion of specific and long-lasting immunity to smallpox and is superior to other routes of immunization

53 over 30 years ago; orthopox viruses such as smallpox and monkeypox remain serious public health thre

54 m may exist during human infections with the smallpox and monkeypox viruses, which are highly homolog

55 s and is highly conserved in most, including smallpox and monkeypox viruses.

56 Smallpox and other orthopoxviruses express virulence fac

57 leaving people susceptible to infections by smallpox and other zoonotic Orthopoxviruses such as monk

58 l previously controlled infections including smallpox and polio and that simple, effective treatment

59 cacy of these vaccines in protection against smallpox and serves as a benchmark against which other v

60 hogen than the agent of smallpox, but absent smallpox and the population-wide immunity engendered dur

61 bioterrorism and the intentional release of smallpox and through natural outbreaks of emerging infec

62 The detection limits for analyzing the Smallpox and TP53 genes correspond to 0.1 nM.

63 Together with plague, smallpox and typhus, epidemics of dysentery have been a

64 roduced by Jenner generated immunity against smallpox and ultimately led to the eradication of the di

65 Clinical differentiation of the disease from smallpox and varicella is difficult.

66 athogenic orthopoxvirus infection of humans (smallpox) and mice (mousepox [ectromelia virus {ECTV}])

67 ariola major virus, the etiological agent of smallpox, and Bacillus anthracis, the bacterial pathogen

68 and include variola, the causative agent of smallpox, and monkeypox, an emerging virus of great conc

69 Variola, the causative agent of smallpox, and the related monkeypox virus are both selec

70 nt for the development of safer vaccines for smallpox- and poxvirus-vectored recombinant vaccines.

71 The threat of smallpox as a bioweapon and the emerging threat of human

72 The threat of a smallpox-based bioterrorist event or a human monkeypox o

73 nes but also as an immunization tool against smallpox because of its potential use as a bioterrorism

74 many infectious diseases such as measles and smallpox because of the ability of vaccination campaigns

75 s efficient human pathogen than the agent of smallpox, but absent smallpox and the population-wide im

76 or public immunization against the spread of smallpox by bioterror, there is serious concern about Dr

77 table exception was the eradication of human smallpox by vaccination over 30 years ago.

78 The samples predate the earliest confirmed smallpox cases by ~1000 years, and the sequences reveal

79 causes mousepox, a surrogate mouse model for smallpox caused by variola virus in humans.

80 Since the eradication of smallpox (caused by an orthopoxvirus (OPXV) related to M

81 Since routine vaccination for smallpox ceased more than 30 years ago, there is concern

82 Smallpox constitutes a major bioterrorism threat, which

83 to develop new therapeutics and vaccines for smallpox continue through their evaluation in animal mod

84 d both alastrim minor, a phenotypically mild smallpox described from the American continents, and iso

85 Variola virus, the causative agent of smallpox, enters and exits the host via the respiratory

86 on in cholera control, a cyclone disaster, a smallpox epidemic, and formal training in ophthalmology

87 smallpox vaccine strain that contributed to smallpox eradication in Brazil.

88 The success of the World Health Organization smallpox eradication program three decades ago resulted

89 scuss the role of surveillance in the global smallpox eradication program, emphasizing that the estab

90 major vaccine producer in Brazil during the smallpox eradication program.

91 dard" for infectious disease eradiation, the Smallpox Eradication Programme, utilized mass immunizati

92 ock-like structure and that the timescale of smallpox evolution is more recent than often supposed, w

93 rts, although it is difficult to distinguish smallpox from other pustular rashes by description alone

94 80, the World Health Assembly announced that smallpox had been successfully eradicated as a disease o

95 First-generation vaccines used to eradicate smallpox had rates of adverse effects that are not accep

96 es has been eliminated in the United States; smallpox has been eradicated worldwide.

97 variola virus (VARV), the etiologic agent of smallpox, has been reported in human populations for >2,

98 Smallpox holds a unique position in the history of medic

99 While the smallpox homolog of VCP is able to bind VACV A56, the ec

100 Outbreaks of smallpox (i.e., caused by variola virus) resulted in up

101 The successful eradication of smallpox in 10 years compares with the target date set i

102 Despite evidence of smallpox in antiquity, a new study of a 350 year-old Lit

103 Although there have been claims of smallpox in Egypt, India, and China dating back millenni

104 Vaccination for smallpox in humans and rinderpest in cattle was the basi

105 that protect from subsequent infections with smallpox in humans or the related ectromelia virus (ECTV

106 tion in cynomolgus macaques, which simulates smallpox in humans, was used to evaluate two vaccines, A

107 ist for >50 years after immunization against smallpox in the absence of re-exposure to VV.

108 ell as variola virus (the causative agent of smallpox) in vitro and to more effectively protect mice

109 ound that the duration of immunity following smallpox infection was remarkably similar to that observ

110 up to 30% mortality, but those who survived smallpox infection were regarded as immune for life.

111 nd the levels and duration of immunity after smallpox infection, we performed a case-control study co

112 Variola major (smallpox) infection claimed hundreds of millions lives b

113 one (IBT), a compound that was used to treat smallpox infections, induced AVGs, suggesting a role for

114 ogs of the human complement regulators named smallpox inhibitor of complement enzymes (SPICE) and vac

115 oals were to characterize the ability of the smallpox inhibitor of complement enzymes, SPICE, to regu

116 se of this surrogate model for testing human smallpox interventions.

117 The current vaccine against smallpox is an infectious form of vaccinia virus that ha

118 inically and immunologically most similar to smallpox is monkeypox, a zoonosis endemic to moist fores

119 A vaccine for smallpox is no longer administered to the general public

120 The eradication of smallpox is one of the greatest medical successes in his

121 y of poxviruses, variola virus (which causes smallpox) is the most pathogenic, while monkeypox virus

122 Variola virus, the causative agent of smallpox, is a potential bioweapon.

123 spite its documented efficacy in eradicating smallpox, is not optimal for the vaccination of contempo

124 Vaccinia virus, the live vaccine for smallpox, is one of the most successful vaccines in huma

125 Variola virus, the causative agent of smallpox, is the most notorious member of the Poxviridae

126 B from variola virus, the causative agent of smallpox, is the most potent TNFR of those tested here i

127 rus, the mouse homolog of the human virus of smallpox, large numbers of CD4(+) T cells in the drainin

128 ant to mousepox (the mouse parallel of human smallpox) lose resistance at mid-age.

129 ng immunity to infectious diseases including smallpox, measles and poliomyelitis.

130 virus (VACV) elicits heterotypic immunity to smallpox, monkeypox, and mousepox, the mechanistic basis

131 the in vivo kinetics of T-cell responses in smallpox/monkeypox.

132 Smallpox, one of the most devastating human diseases, ki

133 otable success of vaccination in eradicating smallpox, one of the world's most lethal diseases.

134 variola virus, the orthopoxvirus that causes smallpox, one-third of infected people succumbed to the

135 eliberate release of infectious agents, such smallpox or a related virus, monkeypox, would have catas

136 in the event of a bioterror attack involving smallpox or anthrax.

137 ndividuals with uncertain exposure status to smallpox or for whom vaccination is contraindicated.

138 atory Orthopoxvirus infection, such as human smallpox or monkeypox, remain to be fully identified.

139 le utility for imatinib mesylate in treating smallpox or MPX infections or complications associated w

140 that ST-246 may be effective in controlling smallpox or other pathogenic orthopoxviruses in some imm

141 ed by severe epidemic events such as plague, smallpox, or influenza that shaped the immune system of

142 Despite the eradication of smallpox, orthopoxviruses (OPV) remain public health con

143 oncolytic virus therapy and vaccines against smallpox, other pathogens, and cancer.

144 y element of the public health response to a smallpox outbreak.

145 In spite of the eradication of smallpox over 30 years ago; orthopox viruses such as sma

146 se observation of individuals with suspected smallpox, plague, or cholera.

147 or preventing many viral diseases, including smallpox, polio, measles, mumps and yellow fever.

148 Smallpox preparedness research has led to development of

149 e development of new antiviral compounds for smallpox prophylaxis and treatment is critical, especial

150 The threat of smallpox release and use as a bioweapon has encouraged t

151 The development of a subunit vaccine for smallpox represents a potential strategy to avoid the sa

152 onses and neutralizing antibody levels of 24 smallpox survivors with the antiviral immunity observed

153 For botulism and smallpox, the frequencies were 0.55% and 0.23%.

154 Plasma pharmacokinetics of ST-246, smallpox therapeutic, was evaluated in mice, rabbits, mo

155 ite concerns regarding the reintroduction of smallpox, there is little enthusiasm for large-scale red

156 Despite eradication of smallpox three decades ago, public health concerns remai

157 n 2011 and is only the second disease, after smallpox, to have ever been eradicated.

158 he amplified, multiplexed analysis of genes (Smallpox, TP53) and metal ions (Ag(+), Hg(2+)).

159 The potential threat of smallpox use in a bioterrorist attack has heightened the

160 s with the antiviral immunity observed in 60 smallpox-vaccinated (i.e., vaccinia virus-immune) contro

161 ntified VACV determinants were recognized by smallpox-vaccinated human peripheral blood cells in a va

162 myo/pericarditis was observed during the US smallpox vaccination (DryVax) campaign initiated in 2002

163 V) related to MPXV) and cessation of routine smallpox vaccination (with the live OPXV vaccinia), ther

164 eratitis is a serious complication following smallpox vaccination and can lead to blindness.

165 ency, attributed in part to the cessation of smallpox vaccination and concomitant waning of populatio

166 hat the levels of immunity induced following smallpox vaccination are comparable in magnitude to that

167 als with atopic dermatitis are excluded from smallpox vaccination because of their propensity to deve

168 Thirty years after mass smallpox vaccination campaigns ceased, human monkeypox i

169 eased significantly due to cessation of mass smallpox vaccination campaigns.

170 nalyse viral vaccine genomes associated with smallpox vaccination from historical artefacts.

171 zed that individuals who develop fever after smallpox vaccination have genetically determined differe

172 factor (IRF1) were associated with AEs after smallpox vaccination in 2 independent study samples.

173 prompts the question of whether cessation of smallpox vaccination is driving the phenomenon, and if s

174 is increasing due to the absence of routine smallpox vaccination leading to a higher proportion of n

175 Eczema vaccinatum (EV) is a complication of smallpox vaccination occurring in patients with atopic d

176 ression changes in 197 recipients of primary smallpox vaccination representing the extremes of humora

177 Eczema vaccinatum (EV) is a complication of smallpox vaccination that can occur in persons with ecze

178 virus keratitis (VACVK) is a complication of smallpox vaccination that can result in blindness.

179 to reveal the evolutionary relationships of smallpox vaccination viruses within the poxviruses as a

180 een candidate SNPs and antibody levels after smallpox vaccination with P < .05.

181 y to CMV and vaccinia virus (previous DryVax smallpox vaccination).

182 ccinia virus (VV) infection, mimicking human smallpox vaccination, greatly increased expression of th

183 Despite the success of smallpox vaccination, the immunological correlates of pr

184 as remarkably similar to that observed after smallpox vaccination, with antiviral T-cell responses th

185 to measure T cells elicited after childhood smallpox vaccination.

186 origins and diversity of the viruses used in smallpox vaccination.

187 lular immunity in subjects following primary smallpox vaccination.

188 ccount for differences in immune response to smallpox vaccination.

189 d areas, male gender, age < 15, and no prior smallpox vaccination.

190 ing to blindness is a severe complication of smallpox vaccination.

191 ukemia and inadvertent autoinoculation after smallpox vaccination.

192 to measure T cells elicited after childhood smallpox vaccination.

193 als who experienced adverse events following smallpox vaccination.

194 reviously assessed for clinical responses to smallpox vaccination.

195 udies focusing on CD4(+) T cell responses to smallpox vaccination.

196 esponses to nonvaccinia OPXV infections from smallpox vaccination.

197 entially lethal complication associated with smallpox vaccination.

198 now that populations do not receive routine smallpox vaccination.

199 Following successful eradication of smallpox, vaccination rates with the smallpox vaccine ha

200 th century, the method, source and origin of smallpox vaccinations remained unstandardised and opaque

201 Two independent clinical trials of the smallpox vaccine (Aventis Pasteur) were conducted in hea

202 als (n = 1071) who received a single dose of smallpox vaccine (Dryvax, Wyeth Laboratories) and examin

203 f protective humoral immunity induced by the smallpox vaccine (vaccinia virus [VACV]).

204 f the human anti-B5 antibody response to the smallpox vaccine (vaccinia virus) are heavily dependent

205 vax vaccine or 1 of 2 lots of Sanofi Pasteur smallpox vaccine and were evaluated for vaccination succ

206 conclude that the protection afforded by the smallpox vaccine anti-EV response is predominantly media

207 , and IL-6 immune responses after receipt of smallpox vaccine are genetically controlled by HLA genes

208 We studied antibody targets in smallpox vaccine by developing potent neutralizing antib

209 Preclinical studies to date with subunit smallpox vaccine candidates, however, have been limited

210 The smallpox vaccine Dryvax, which consists of replication-c

211 ration as an alternative to the conventional smallpox vaccine Dryvax.

212 heightened the need to develop an effective smallpox vaccine for immunization of the general public.

213 e evolutionary relationship of the different smallpox vaccine genomes during the centuries.

214 tion of smallpox, vaccination rates with the smallpox vaccine have significantly dropped.

215 cells underwent 3-week-long expansion after smallpox vaccine immunization and displayed simple reexp

216 munospot assay [ELISPOT]) immune response to smallpox vaccine in 1076 immunized individuals.

217 es regulating the humoral immune response to smallpox vaccine in both Caucasians and African American

218 horsepox and horsepox-related viruses as the smallpox vaccine in the nineteenth century.

219 The smallpox vaccine is associated with more serious adverse

220 Smallpox vaccine is considered a gold standard of vaccin

221 Smallpox vaccine is contraindicated in immunosuppression

222 Studying the immune protection mechanism of smallpox vaccine is important for understanding the basi

223 Moreover, the safety of the smallpox vaccine is of great concern, as complications m

224 The smallpox vaccine is widely considered the gold standard

225 onses upon vaccination, since its use as the smallpox vaccine led to the eradication of one of the wo

226 in IOC (VACV-IOC) was the seed strain of the smallpox vaccine manufactured by the major vaccine produ

227 enuated cell culture-adapted Lister vaccinia smallpox vaccine missing the B5R protein and licensed fo

228 etween HLA alleles and 15 immune outcomes to smallpox vaccine on a per-locus and a per-allele level.

229 Why this is the case and how the smallpox vaccine overcomes this challenge remain incompl

230 Smallpox vaccine provided protection against both infect

231 ntially lethal complication that develops in smallpox vaccine recipients with severely impaired cellu

232 es in mediating adaptive immune responses to smallpox vaccine remains unknown.

233 recent common ancestor, probably an ancient smallpox vaccine strain related to horsepox virus.

234 rization of two clones of VACV-IOC, a unique smallpox vaccine strain that contributed to smallpox era

235 ne (Wyeth/IL-15/PA) using the licensed Wyeth smallpox vaccine strain that is efficacious against both

236 Altogether, these data indicate the smallpox vaccine succeeds in generating strong neutraliz

237 The smallpox vaccine using vaccinia virus has been highly su

238 rsistent infections, influenza virus and the smallpox vaccine virus (vaccinia virus), were studied.

239 dual MHC-II-restricted vaccinia virus (VACV, smallpox vaccine) epitopes revealed that CD4(+) T cell h

240 The licensed smallpox vaccine, ACAM2000, is a cell culture derivative

241 Smallpox vaccine, arguably the most effective vaccine in

242 While the smallpox vaccine, Dryvax or Dryvax-derived ACAM2000, hol

243 Vaccination with the current smallpox vaccine, Dryvax, produces protective immunity b

244 MVA is a promising candidate as a safer smallpox vaccine, even for immunocompromised individuals

245 n of Wyeth Dryvax vaccine and Sanofi Pasteur smallpox vaccine, given that the resulting morbidity sho

246 cinia virus (VACV), the virus comprising the smallpox vaccine, induces memory CD8(+) T cells that pro

247 t 1 and 3-5 weeks after vaccination with the smallpox vaccine, serial measurements have not been perf

248 virus strains, including the current clonal smallpox vaccine, that the ability of a strain to spread

249 Using vaccinia virus (VACV), the smallpox vaccine, we report that the VACV BBK protein A5

250 antibody responses that are elicited by the smallpox vaccine, which has enabled the first eradicatio

251 ding of the central protective activities of smallpox vaccine-elicited antibodies in immunized humans

252 e or cytokine receptor gene polymorphisms in smallpox vaccine-induced adaptive immunity.

253 IL18R1 and IL18 genetic loci for broad-based smallpox vaccine-induced adaptive immunity.

254 Our results demonstrate that variations in smallpox vaccine-induced cytokine responses are modulate

255 similarities of antigenic protein targets of smallpox vaccine-induced responses in humans and prairie

256 The mechanisms underlying smallpox vaccine-induced variations in immune responses

257 f 1056 healthy adults after a single dose of smallpox vaccine.

258 he polyclonal human antibody response to the smallpox vaccine.

259 n of a safe alternative to the existing live smallpox vaccine.

260 Vaccinia virus is the smallpox vaccine.

261 ination and thus provide a safer alternative smallpox vaccine.

262 that this is a fundamental attribute of the smallpox vaccine.

263 ristic of the human antibody response to the smallpox vaccine.

264 viral neutralization and part of the Dryvax smallpox vaccine.

265 None of the smallpox vaccines caused illness in this model, and all

266 Smallpox vaccines containing vaccinia virus elicit stron

267 study, we tested current and investigational smallpox vaccines for safety, induction of anti-OPXV ant

268 nced and partially assembled five genomes of smallpox vaccines from the nineteenth century.

269 omised individuals, a group for whom current smallpox vaccines have an unacceptable safety profile.

270 This evaluation of different human smallpox vaccines in cynomolgus macaques helps to provid

271 model for the safety and efficacy testing of smallpox vaccines in pre- and postexposure vaccine testi

272 Therefore, the development of safer smallpox vaccines that can match the immunogenicity and

273 Therefore, the search for new-generation smallpox vaccines that combine low pathogenicity, immune

274 Alternative smallpox vaccines with an improved safety profile would

275 esponding to the live yellow fever virus and smallpox vaccines--two highly successful human vaccines.

276 us complications associated with traditional smallpox vaccines.

277 rant further assessment as candidate subunit smallpox vaccines.

278 infections, and the side effects of existing smallpox vaccines.

279 od options for alternative second-generation smallpox vaccines.

280 les of the poxviral complement inhibitors of smallpox, vaccinia, and monkeypox known as SPICE, VCP (o

281 pre-modern bubonic plague (Yersinia pestis), smallpox (Variola virus) and cholera (Vibrio cholerae) -

282 Immunization against smallpox (variola virus) with Dryvax, a live vaccinia vi

283 oxviruses (OPVs), which include the agent of smallpox (variola virus), the zoonotic monkeypox virus,

284 1L protein is a potent vaccinia and variola (smallpox) virulence factor.

285 Orthopoxviruses (OPVs), such as the human smallpox virus and the mouse-equivalent ectromelia virus

286 tures of human RCA (MCP, DAF, and CR1) and a smallpox virus homolog (SPICE) bound to complement compo

287 The K7L gene product of the smallpox virus is a protease implicated in the maturatio

288 Vaccinia virus (VACV), a close relative of smallpox virus, is thought to exploit cell motility as a

289 domain and a chemokine-binding domain called smallpox virus-encoded chemokine receptor (SECRET) domai

290 inC1, and A39R is a Sema7A mimic secreted by smallpox virus.

291 Poxviruses including vaccinia and smallpox viruses express PKR inhibitors such as the vacc

292 Smallpox was declared eradicated in 1980 after an intens

293 Although smallpox was eradicated as a global illness more than 30

294 zing antibodies induced after infection, but smallpox was eradicated before contemporary methods for

295 onse in people previously vaccinated against smallpox was evaluated by the inclusion of vaccinia-expe

296 without affecting cell viability.IMPORTANCE Smallpox was one of the most devastating diseases in hum

297 strains, the more clinically severe form of smallpox, which spread from Asia either 400 or 1,600 YBP

298 of hepatitis C, avian influenza (H5N1), and smallpox without making changes to the underlying assay.

299 as used as a live-virus vaccine to eradicate smallpox worldwide and has recently received considerabl

300 xvirus and was the vaccine used to eradicate smallpox, yet the expression profiles of many of its gen